Randomized Phase III Trial of Multimodality Therapy Versus Standard of Care Systemic Therapy in HER2 Positive (HER2+) De Novo (AJCC Stage IV) Oligometastatic Breast Cancer With Response to Initial Chemotherapy

This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating patients with HER2-positive stage IV breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or to a limited number of sites (oligometastatic). The usual approach for patients with (oligo)metastatic HER2-positive breast cancer is systemic drug treatment, which means medicines that travel through the whole body to treat both the breast and any areas where the cancer has spread. There are a number of approved HER2-targeted systemic therapy regimens available to patients. These typically include immunotherapy and/or chemotherapy. Immunotherapy drugs may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Unlike systemic therapy, locoregional therapies like surgery and radiation are focused treatments at the site of disease, delivered with the intent of sparing healthy tissues. Breast surgeries such as breast conserving therapy or total mastectomy are procedures in which the cancerous breast tissue (and healthy breast tissue in the case of total mastectomy) are surgically removed from the body. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Adding locoregional therapy, as well as metastasis-directed SBRT, to standard systemic therapy may help patients with (oligo)metastatic, HER2-positive stage IV breast cancer live longer overall or before their cancer progresses, and may help more patients achieve no evidence of disease, when compared to standard systemic therapy alone.

开始日期2027-03-09

申办/合作机构

SWOG

[+1]

NCT07126561

/ Not yet recruiting临床2期IIT

Phase II Open Label Trial of Trastuzumab Deruxtecan (Enhertu, DS-8210) in HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2

Purpose: This clinical trial is designed to evaluate the safety and effectiveness of Trastuzumab Deruxtecan for patients with HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer. The goal is to determine how well this treatment works and to identify any potential side effects.
Who Can Participate: We are looking for Participants with histologically confirmed HER2 positive locally advanced unresectable and/or metastatic esophageal, gastric or GEJ adenocarcinoma with an ECOG PS of 2 and measurable disease according to RECIST 1.1 within 42 days prior to registration. Participants will be carefully screened to ensure they meet the study requirements.
What to Expect: Participants will undergo 6.4mg/kg, IV infusion of Trastuzumab deruxtucan over the course of the study. They will receive detailed information about the study and will have the opportunity to ask questions before deciding to participate. Informed consent will be obtained to ensure that participants understand the study's purpose, procedures, risks, and benefits.
Safety Monitoring: The health and safety of participants are our top priority. An Independent Data and Safety Monitoring Committee (DSMC) will regularly review the study data to ensure participant safety and to monitor for any adverse events. Any serious side effects will be reported and addressed promptly.
Benefits and Risks: While the study aims to provide potential benefits, such as improved treatment options for HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer there may also be risks involved. Participants will be informed of all possible risks before enrolling in the study.
Confidentiality: All personal information will be kept confidential, and data will be used only for research purposes.
Contact Information: For more information about this study, please contact PhaseIICRA@medicine.bsd.uchicago.edu

开始日期2026-11-01

申办/合作机构

The University of Chicago

NCT07137416

/ Recruiting临床1期IIT

Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients With HER2 Expressing Solid Tumors

This phase I trial tests the safety, side effects, and best dose of pidnarulex in combination with trastuzumab deruxtecan in treating patients with breast cancer and other solid tumors that express varying levels of a protein called HER2 and that has spread from where it first started (primary site) to other places in the body (metastatic), that cannot be removed by surgery (unresectable), or that has spread to nearby tissue or lymph nodes (locally advanced). Pidnarulex is an enzyme inhibitor that causes cell death and prevents tumor cell growth. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Giving pidnarulex in combination with trastuzumab deruxtecan may be safe, tolerable and/or effective in treating patients with metastatic, unresectable, or locally advanced HER2-expressing breast cancer or other solid tumors.

开始日期2026-10-05

申办/合作机构

National Cancer Institute

100 项与德曲妥珠单抗相关的临床结果

登录后查看更多信息

100 项与德曲妥珠单抗相关的转化医学

登录后查看更多信息

100 项与德曲妥珠单抗相关的专利（医药）

登录后查看更多信息

1,148

项与德曲妥珠单抗相关的文献（医药）

2026-10-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

An intrinsically hydrophilic linker enables a stable, high-DAR exatecan-based HER2 ADC with potent antitumor activity

Article

作者: Feng, Chaoyang ; Ma, Jianglei ; Wu, Chenglong ; Bao, Yiwen ; Huang, Jinkun ; Heng, Xiaojie ; Zeng, Nan ; Yang, Tingting ; Ni, Dechun

Antibody-drug conjugates (ADCs) combine the targeting specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs. However, ADC development using Exatecan, a potent topoisomerase I inhibitor, has been challenged by its hydrophobicity, leading to aggregation, rapid clearance, and off-target toxicity. Herein, we report the design of an intrinsically hydrophilic drug-linker platform (SMP-70067-L) that enables the construction of a homogeneous Exatecan-based HER2-targeted ADC (SMP-70067-X) with a high drug-to-antibody ratio (DAR of 7.92). Similar to Trastuzumab deruxtecan (DS-8201a), which achieves high DAR without PEG or polysarcosine chains through a hydrophilic self-immolative spacer, SMP-70067-L integrates minimal hydrophilic elements, including a glutamic acid residue and a modified aromatic self-immolative spacer, to balance hydrophilicity, stability, and efficient payload release. The resulting ADC exhibits low aggregation (<1%), favorable plasma and thermal stability, and sustained exatecan release. SMP-70067-X demonstrates potent cytotoxicity in HER2-positive tumor cells (sub-nanomolar IC₅₀ values) and significantly enhanced antitumor efficacy compared to DS-8201a in HER2-moderate and HER2-low xenograft models. These results highlight the critical role of rational linker engineering in expanding the therapeutic window of hydrophobic topoisomerase I inhibitor-based ADCs.

2026-07-01·Respiratory Investigation

Response to trastuzumab deruxtecan in postoperative recurrent lung adenocarcinoma harboring concurrent EGFR and HER2 mutations after progression on adjuvant osimertinib

Article

作者: Muramoto, Kei ; Naito, Daiki ; Goebuchi, Kageaki ; Fukushima, Kazuaki ; Akaike, Kimitaka ; Furukawa, Tsuguhiro ; Saruwatari, Koichi ; Sakagami, Takuro ; Tomita, Yusuke ; Nishiyama, Taketaka ; Okabayashi, Hiroko

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) mutations are key molecular targets in non-small cell lung cancer (NSCLC). We report a rare case of postoperative recurrent lung adenocarcinoma in an 84-year-old woman harboring EGFR L858R and HER2 S310F mutations after progression on adjuvant osimertinib. After further progression on chemotherapy, she received trastuzumab deruxtecan (T-DXd), which induced metastatic regression and yielded disease control for approximately 6 months. This case highlights a therapeutic approach for NSCLC with multiple driver alterations and demonstrates the clinical activity of T-DXd in osimertinib-refractory EGFR-mutant disease with a concurrent HER2 alteration.

2026-07-01·iScience

The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads

Article

作者: Chung, Heekyung ; Meric-Bernstam, Funda ; Guo, Xiao ; Cabrera, Erika ; Lackner, Mark R ; Harismendy, Olivier ; Lee, Catherine ; Kim, Doris ; Ma, Jianhui

Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy, yet strategies to overcome resistance and enhance efficacy remain needed. Since ADCs exert anti-tumor effects via DNA damage or mitotic disruption, combining them with WEE1 inhibitors represents a rational approach. We investigated the selective WEE1 inhibitor azenosertib in combination with ADCs carrying topoisomerase I inhibitor (TOP1i) or microtubule inhibitor (MTI) payloads. Azenosertib enhanced the activity of free TOP1i agents and TOP1i-based ADCs (trastuzumab deruxtecan [T-DXd] and sacituzumab govitecan), increasing DNA damage and apoptosis, and extended the duration of response while overcoming T-DXd resistance in patient-derived xenografts. Synergistic effects were also observed with MTI agents and MTI-based ADCs (mirvetuximab soravtansine, tisotumab vedotin, and enfortumab vedotin), associated with exacerbated mitotic defects and prolonged mitotic arrest. All combinations enhanced efficacy and were well tolerated in vivo. These findings position azenosertib as a broadly applicable enhancer of cytotoxic-payload ADCs, offering a promising strategy for patients with advanced solid tumors.

6,825

项与德曲妥珠单抗相关的新闻（医药）

2026-07-20

·ioncology

ESMO 2026丨瞭望前瞻，百余项中国乳腺癌研究亮相ESMO，一文速览

点击蓝字，关注我们编者按：2026年欧洲肿瘤内科学会年会（ESMO 2026）将于10月23日至27日在西班牙马德里召开。作为全球肿瘤领域最具影响力的年度盛会之一，ESMO每年覆盖基础研究、转化医学与临床诊疗全维度前沿进展，是国际肿瘤学界交流学术成果、更新诊疗理念的核心平台。目前，ESMO官网已公布部分摘要标题，《肿瘤瞭望》特针对乳腺癌领域的中国入选研究进行系统梳理，供读者提前把握本次大会的中国学术动态。（由于目前多数研究摘要全文尚未正式发布，本次整理仅基于已公开的标题信息，如有疏漏或表述偏差，敬请留言指正。）快速口头报告摘要号：4RO 英文标题：Target switching with conserved-payload novel ADCs in patients with metastatic breast cancer following prior ADC therapy (SWITCH): a prospective, open-label, phase 2 platform trial 中文标题：转移性乳腺癌ADC经治后采用同载荷异载荷新型ADC的靶点转换研究：一项前瞻性、开放标签的 II 期平台试验（SWITCH）讲者：刘西禹 (复旦大学附属肿瘤医院) 摘要号：5RO 英文标题：Safety and efficacy of SYS6043, a Novel B7-H3–Targeting Antibody-Drug Conjugate, in Patients with Advanced breast cancer 中文标题：新型靶向B7-H3 ADC SYS6043治疗晚期乳腺癌的安全性与有效性讲者：王红霞 (复旦大学附属肿瘤医院) 摘要号：4639RO 英文标题：Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01 中文标题：芦康沙妥珠单抗对比化疗用于既往经治局部复发或转移性三阴性乳腺癌的III期OptiTROP-Breast01研究最终OS分析讲者：樊英 (中国医学科学院肿瘤医院) 摘要号：4640RO 英文标题：Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4–Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (TopI)-Based ADCs: Results from a Phase 2 Study 中文标题：新型靶向Nectin-4 ADC bulumtatug Fuvedotin（BFv，9MW2821）在既往接受过拓扑异构酶I抑制剂为基础的ADC治疗的局部晚期或转移性三阴性乳腺癌（la/mTNBC）患者中显示出显著疗效：一项II期临床研究的结果讲者：张剑 (复旦大学附属肿瘤医院) 壁报 Basic science（基础科学）摘要号：399P 英文标题：C15orf48 drives breast cancer liver metastasis via glutathione dependent activation of Wnt/β-catenin signaling 中文标题：C15orf48通过谷胱甘肽依赖性激活Wnt/β-catenin信号通路驱动乳腺癌肝转移讲者：宋振川（河北医科大学第四医院） Advanced breast cancer, other（晚期乳腺癌，其他）摘要号：6P 英文标题：Machine learning model based on pathomics features predicts T-DXd response in advanced breast cancer 中文标题：基于病理组学特征的机器学习模型可预测晚期乳腺癌对T-DXd治疗的反应讲者：刘月平（河北医科大学第四医院）摘要号：10P 英文标题：A randomized phase 3 study of disitamab vedotin (DV) versus chemotherapy (chemo) in HER2-low advanced breast cancer: overall and the liver metastasis (BCLM) subgroup results 中文标题：维迪西妥单抗对比化疗治疗HER2低表达晚期乳腺癌的随机III期研究：总体及肝转移亚组结果讲者：王佳玉（中国医学科学院肿瘤医院）摘要号：19P 英文标题：Ribociclib plus endocrine therapy versus chemotherapy in patients with rapidly progressive HR+/HER2− advanced breast cancer: a multicenter phase II study with external controls 中文标题：瑞波西利联合内分泌治疗对比化疗用于快速进展HR+/HER2−晚期乳腺癌：一项多中心II期研究及外部对照讲者：Min Tian (Nanjing, China) 摘要号：26P 英文标题：Efficacy and Safety of Anlotinib-Based Therapy in Advanced Breast Cancer: A Real-World Study 中文标题：以安罗替尼为基础方案治疗晚期乳腺癌的真实世界疗效与安全性研究讲者：姚静（华中科技大学同济医学院附属协和医院）摘要号：27P 英文标题：Local treatment in metastatic breast cancer with oligoprogression: a retrospective cohort study and reconstructive individual patient data meta-analysis 中文标题：寡进展转移性乳腺癌的局部治疗：回顾性队列研究与重建个体患者数据荟萃分析讲者：Haoting Shi (Shanghai, China) 摘要号：73eP 英文标题：Chidamide combined with Vinorelbine and Capecitabine for HER2-Negative Advanced Breast Cancer: A Single-Arm, Single-Center, Phase II Clinical Trial 中文标题：西达本胺联合长春瑞滨和卡培他滨治疗HER2阴性晚期乳腺癌：一项单臂、单中心II期临床试验讲者：La Zou (Chongqing, China) 摘要号：74eP 英文标题：Intraventricular thiotepa in combination with methotrexate for leptomeningeal metastasis from breast cancer (NJMU-BC04): a single-arm phase II study 中文标题：脑室内注射塞替哌联合甲氨蝶呤治疗乳腺癌软脑膜转移（NJMU-BC04）：一项单臂II期研究讲者：Mengyao Zha (Nanjing, China) 摘要号：79eP 英文标题：Eribulin After Antibody-Drug Conjugate Treatment in Metastatic Breast Cancer: A Real-World Multicenter Retrospective Study 中文标题：抗体偶联药物治疗后应用艾立布林治疗转移性乳腺癌：一项真实世界多中心回顾性研究讲者：邵彬（北京大学肿瘤医院）摘要号：83eP 英文标题：An EGFR dominating triple positive tumor clone engages cycling M2 macrophages during disease progression following bispecific HER3/EGFR antibody-drug conjugate (ADC) treatment in metastatic breast cancer 中文标题：EGFR主导的三阳性肿瘤克隆在转移性乳腺癌双特异性HER3/EGFR ADC治疗后疾病进展中招募循环M2巨噬细胞讲者：吕铮（吉林大学第一医院）摘要号：96eP 英文标题：Real-world effectiveness of antibody-drug conjugates versus conventional systemic therapies in metastatic breast cancer: An inverse probability of treatment weighting analysis 抗体偶联药物对比传统全身治疗在转移性乳腺癌中的真实世界疗效：逆概率处理加权分析讲者：Shukai Guo (Fuzhou, China) Breast cancer, early stage（早期乳腺癌）摘要号：547P 英文标题：Predictive Role of ctDNA for Pseudoprogression in Triple-Negative Breast Cancer during Neoadjuvant Immunotherapy 中文标题：ctDNA在三阴性乳腺癌新辅助免疫治疗期间假性进展的预测作用讲者：王永胜（山东省肿瘤医院）摘要号：560P 英文标题：Efficacy and Safety of Pyrotinib Combined with Trastuzumab and Aromatase Inhibitor in Neoadjuvant Treatment of HER2+/HR+ Breast Cancer: A Single-Arm, Multi-Center Phase II Exploratory Study 中文标题：吡咯替尼联合曲妥珠单抗和芳香化酶抑制剂新辅助治疗HR+/HER2+乳腺癌：一项单臂、多中心II期探索性研究讲者：葛洁（天津医科大学肿瘤医院）摘要号：570P 英文标题：Qualitative synergism between female hormone use and secondhand smoke on breast carcinogenesis: A prospective cohort study 中文标题：雌激素使用与二手烟在乳腺癌发生中的定性协同作用：一项前瞻性队列研究讲者：Hong-Hong Zhu (Quzhou, China) 摘要号：580P 英文标题：Ki-67-Guided Stratification and Resistance Mechanism Analysis of CDK4/6 Inhibitor Therapy Following Adaptive Neoadjuvant Endocrine Treatment in HR+/HER2− Breast Cancer 中文标题：HR+/HER2-乳腺癌中适应性新辅助内分泌治疗后CDK4/6抑制剂治疗的Ki-67引导分层与耐药机制分析讲者：王永胜（山东省肿瘤医院）摘要号：616eP 英文标题：Radiotherapy-Integrated Neoadjuvant Therapy Deepens Response and Expands Eligibility for Surgery Omission in TNBC and HR-/HER2+ Breast Cancer: Interim Analysis of a Multicenter Phase II Study 中文标题：放疗联合新辅助治疗可增强对TNBC和HR-/HER2+乳腺癌的疗效，并扩大免手术治疗发适应证：一项多中心II期研究期中分析讲者：杨正军（天津医科大学肿瘤医院）摘要号：617eP 英文标题：Ultrasound-Guided Vacuum-Assisted Excision Followed by Definitive Surgery in Early-Stage Small Breast Cancer: A Single-Arm Trial 中文标题：超声引导下真空辅助旋切术后续根治性手术治疗早期小乳腺癌：一项单臂试验讲者：Siyuan Wang (Xi'an, China) 摘要号：628eP 英文标题：Extended Sentinel Lymph Node Biopsy Using a Single Tracer After Neoadjuvant Therapy for Breast Cancer: A Retrospective Real-World Study 中文标题：乳腺癌新辅助治疗后应用单一示踪剂的扩展前哨淋巴结活检：一项回顾性真实世界研究讲者：张聚良（空军军医大学西京医院）摘要号：635eP 英文标题：Profound Vitamin D Deficiency Identifies Elevated Heart Failure Risk Among Breast Cancer Survivors: A UK Biobank Multi-State Analysis 中文标题：重度维生素D缺乏识别乳腺癌幸存者中升高的心力衰竭风险：一项UK Biobank多状态分析讲者：Yiyin Zhang (Beijing, China) 摘要号：636eP 英文标题：A novel single-molecule dual CDK4/CDK2 inhibitor series with cytotoxic cellular activity and improved kinome selectivity for HR+/HER2− breast cancer and CCNE1-amplified ovarian cancer 中文标题：新型单分子双靶点CDK4/CDK2抑制剂系列：针对HR+/HER2−乳腺癌和CCNE1扩增卵巢癌具有细胞毒活性和改善的激酶组选择性讲者：Xianqiang Sun (Shanghai, China) 摘要号：639eP 英文标题：Carbon Nano-Lymph Tracer in Modified Radical Mastectomy After Neoadjuvant Chemotherapy for Breast Cancer 中文标题：纳米碳淋巴示踪剂在乳腺癌新辅助化疗后改良根治术中的应用讲者：Feng Liu (Fuyang, China, Anhui) 摘要号：646eP 英文标题：Patient and Oncologist Preferences Regarding CDK4/6 Inhibitor Adjuvant Therapy for HR+/HER2- Early Breast Cancer in China 中文标题：中国HR+/HER2−早期乳腺癌患者与肿瘤科医生对CDK4/6抑制剂辅助治疗的偏好讲者：郝春芳（天津医科大学肿瘤医院）摘要号：648eP 英文标题：Standard imaging-guided, Doppler-free chest wall perforator flap reconstruction for granulomatous lobular mastitis: A simplified approach for resource-limited settings 中文标题：标准影像引导下，无多普勒胸壁穿支皮瓣重建术治疗肉芽肿性小叶性乳腺炎：面向资源有限地区的简化方案讲者：王子莹（常州市第一人民医院） HER2+ breast cancer（HER2阳性乳腺癌）摘要号：1772P 英文标题：A Study Evaluating the Safety and Efficacy of Pyrotinib Dose Escalation Plus Loperamide Prophylaxis in First-Line Treatment of Advanced HER2-Positive Breast Cancer 中文标题：一项评估吡咯替尼剂量递增联合洛哌丁胺预防HER2阳性晚期乳腺癌一线治疗中安全性与有效性的研究讲者：晁腾飞（华中科技大学同济医学院附属同济医院）摘要号：1773P 英文标题：Neoadjuvant Oral Paclitaxel Plus Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab in Stage II-III HER2+ Breast Cancer: First-Stage Results from a Simon's Two-Stage Study 中文标题：口服紫杉醇联合皮下注射固定剂量帕妥珠单抗/曲妥珠单抗新辅助治疗II-III期HER2+乳腺癌：Simon两阶段设计第一阶段结果讲者：Yudong Li (Guangzhou, China) 摘要号：1775P 英文标题：Dalpiciclib plus Pyrotinib-Based Chemotherapy-Free Regimens as first line treatment in Trastuzumab-Sensitive, HER2-Positive Metastatic Breast Cancer (DAP-HER-02): A Dual-Cohort, Phase II Study 中文标题：达尔西利联合吡咯替尼无化疗方案一线治疗曲妥珠单抗敏感的HER2阳性转移性乳腺癌（DAP-HER-02）：一项双队列II期研究讲者：牛李敏（郑州大学第一附属医院）摘要号：1776P 英文标题：IBI354 plus pertuzumab as first-line (1L) treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer: Results from a phase 2 study 中文标题：IBI354联合帕妥珠单抗一线治疗HER2阳性不可切除局部晚期或转移性乳腺癌：一项II期研究结果讲者：曾晓华（重庆大学附属肿瘤医院）摘要号：1778P 英文标题：Updated results of SHR-A1811 plus pertuzumab in human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic breast cancer: a phase 1b/2 study 中文标题：SHR-A1811联合帕妥珠单抗治疗HER2阳性不可切除/转移性乳腺癌的更新结果：一项Ib/II期研究讲者：黄香（南京医科大学第一附属医院）摘要号：1779P 英文标题：Prognostic Impact of PIK3CA Mutations in HER2-Positive Advanced Breast Cancer: A Real-World Multicenter Study 中文标题：PIK3CA突变对HER2阳性晚期乳腺癌的预后影响：一项真实世界多中心研究讲者：王瓯晨（温州医科大学附属第一医院）摘要号：1781P 英文标题：Real-World Comparative Study of Pertuzumab- vs Pyrotinib-Based First-Line Regimens in HER2-Positive Advanced Breast Cancer: A Xinjiang Multicenter Study 中文标题：帕妥珠单抗对比吡咯替尼一线治疗HER2阳性晚期乳腺癌的真实世界比较：一项新疆多中心研究讲者：赵兵（新疆医科大学附属肿瘤医院）摘要号：1802eP 英文标题：Neoadjuvant Chemotherapy plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer: A Prospective, Single-arm, Multi-center Study (NEOTORCH-BREAST05) 中文标题：新辅助化疗联合吡咯替尼和曲妥珠单抗治疗HER2阳性乳腺癌：一项前瞻性、单臂、多中心研究（NEOTORCH-BREAST05）讲者：Zhijun Dai (Hangzhou, China) 摘要号：1803eP 英文标题：Multicenter, phase II study of eribulin, carboplatin, trastuzumab and pertuzumab as neoadjuvant therapy in HER2-positive early or locally advanced breast cancer 中文标题：艾立布林、卡铂、曲妥珠单抗和帕妥珠单抗新辅助治疗HER2阳性早期或局部晚期乳腺癌的多中心II期研究讲者：Di Lu (Chengdu, China) 摘要号：1810eP 英文标题：Inetetamab Combined with Pyrotinib for HER2-Positive Advanced Breast Cancer: A Multicenter Real-World Retrospective Study 中文标题：伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌：一项多中心真实世界回顾性研究讲者：Zenggui Wu (Taizhou, China) 摘要号：1812eP 英文标题：Enhanced protein lactylation accompanies acquired resistance to trastuzumab deruxtecan in HER2-positive breast cancer 中文标题：增强的蛋白乳酰化伴随HER2阳性乳腺癌对德曲妥珠单抗的获得性耐药讲者：Nan Jin (Nanjing, China) 摘要号：1814eP 英文标题：Antibody-programmable MOFs reshape multi-dimensional intervention strategies for programmed cell death in HER2+ breast cancer 中文标题：抗体可编程金属有机框架重塑HER2+乳腺癌程序性细胞死亡的多维干预策略讲者：王宇（首都医科大学附属北京同仁医院）摘要号：1818eP 英文标题：Characterization of Antibody Drug Conjugate-Associated Interstitial Lung Disease in Breast Cancer: A Systematic Review and Meta-Analysis 中文标题：乳腺癌抗体偶联药物相关间质性肺病的特征：系统综述与荟萃分析讲者：Yinuo Dong (Beijing, China) 摘要号：1823eP 英文标题：Ranking of First-Line Treatments for Advanced HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis 中文标题：HER2阳性晚期乳腺癌一线治疗的排序：贝叶斯网络荟萃分析讲者：Yuxin Sun (Beijing, China) 摘要号：1828eP 英文标题：Breast Ultrasound for Early Prediction of Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Real-World Analysis 中文标题：乳腺超声用于HER2阳性乳腺癌新辅助治疗疗效早期预测的真实世界分析讲者：Yuhang Xiao (Nanjing, China) 摘要号：1838eP 英文标题：FAP Expression Heterogeneity Drives Efficacy Variation of Targeted Radioligand Therapy and Patient Selection in HER2-Positive Breast Cancer 中文标题：FAP表达异质性驱动HER2阳性乳腺癌靶向放射性配体治疗的疗效差异与患者筛选讲者：Ting Wu (Luzhou, China) 摘要号：1841eTiP 英文标题：Al18F-HER2-BCH PET/CT guided precision neoadjuvant therapy for HER2-positive early breast cancer: FHERNAT trial 中文标题：Al18F-HER2-BCH PET/CT引导的HER2阳性早期乳腺癌精准新辅助治疗：FHERNAT试验讲者：梁旭（北京大学肿瘤医院） HR+ breast cancer（激素受体阳性乳腺癌）摘要号：1847P 英文标题：SHR-A2102, a Nectin-4-directed antibody drug conjugate (ADC), in pretreated HR+/HER2- advanced breast cancer: results from a phase 1 study 中文标题：SHR-A2102（靶向Nectin-4的ADC）用于经治HR+/HER2−晚期乳腺癌：一项I期研究结果讲者：闫敏（郑州大学附属肿瘤医院）摘要号：1848P 英文标题：First-in-human study of JYP0035, a highly selective PI3Kα inhibitor, as monotherapy in patients with advanced solid tumors 中文标题：高选择性PI3Kα抑制剂JYP0035单药治疗晚期实体瘤的首次人体研究讲者：孟艳春（复旦大学附属肿瘤医院）摘要号：1849P 英文标题：A Phase 1b/2 Study of JS105 in Combination with Dalpiciclib and Fulvestrant in Patients with Advanced Breast Cancer 中文标题：JS105联合达尔西利和氟维司群治疗晚期乳腺癌的Ib/II期研究讲者：闫敏（郑州大学附属肿瘤医院）摘要号：1852P 英文标题：Evaluation of the safety and efficacy of SH3765 in combination with fulvestrant in HR+/HER2− advanced breast cancer: a phase Ib study 中文标题：SH3765联合氟维司群治疗HR+/HER2−晚期乳腺癌的安全性与疗效评估：一项Ib期研究讲者：潘跃银（中国科学技术大学附属第一医院）摘要号：1858P 英文标题：BL0175 Injection for Locally Advanced/Metastatic HR+/HER2− Breast Cancer: Preliminary Results from Dose Escalation Stage of a Phase 1 Study 中文标题：BL0175注射液治疗局部晚期/转移性HR+/HER2−乳腺癌：I期剂量递增阶段初步结果讲者：王楠娅（吉林大学第一医院）摘要号：1859P 英文标题：First-line fovinaciclib for advanced breast cancer: updated analysis of a randomized, double-blind phase 3 study 中文标题：伏维西利一线治疗晚期乳腺癌：随机双盲III期研究更新分析讲者：袁芃（中国医学科学院肿瘤医院）摘要号：1869P 英文标题：Lysine acetyltransferase 6A (KAT6A) for predicting tamoxifen resistance in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer 中文标题：赖氨酸乙酰转移酶6A预测HR+/HER2−早期乳腺癌他莫昔芬耐药讲者：Tan Yujing (Beijing, China) 摘要号：1881P 英文标题：Clinical outcomes of YL202/BNT326 (HER3 ADC) in advanced/metastatic HR+/HER2-null/low breast cancer in chemotherapy-naïve and exposed patients 中文标题：YL202/BNT326（HER3 ADC）在初治和经治晚期/转移性HR+/HER2零表达/低表达乳腺癌中的临床结局讲者：孟艳春（复旦大学附属肿瘤医院）摘要号：1886TiP 英文标题：A phase I/II study of GenSci145 as monotherapy or combination therapy in PIK3CA-mutated advanced solid tumors 中文标题：GenSci145单药或联合治疗PIK3CA突变晚期实体瘤的I/II期研究讲者：徐兵河（中国医学科学院肿瘤医院）摘要号：1890eP 英文标题：Integrated Molecular Profiling of Paired Tumor Tissue and Circulating Tumor DNA in Chinese Patients with HR+/HER2- Advanced Breast Cancer Prior to First-Line Systemic Therapy 中文标题：中国HR+/HER2−晚期乳腺癌患者一线全身治疗前配对肿瘤组织与循环肿瘤DNA的整合分子分型讲者：岳健（中国医学科学院肿瘤医院）摘要号：1892eP 英文标题：An Open-label, Single-arm Study of Dalpiciclib in Combination with Aromatase Inhibitor and Capecitabine as Neoadjuvant Therapy for high-risk HR+/HER2- Early Breast Cancer 中文标题：达尔西利联合芳香化酶抑制剂和卡培他滨新辅助治疗高危HR+/HER2−早期乳腺癌：一项开放标签、单臂研究讲者：韩忠华（福建医科大学附属协和医院）摘要号：1893eP 英文标题：Dalpiciclib combined with endocrine therapy and capecitabine in high-risk HR+/HER2- advanced breast cancer: a multicenter phase II study 中文标题：达尔西利联合内分泌治疗和卡培他滨治疗高危HR+/HER2−晚期乳腺癌：一项多中心II期研究讲者：张捷（福建医科大学附属协和医院）摘要号：1895eP 英文标题：Early Toxicity-Driven Dose Modification Preserves Efficacy of Adjuvant Abemaciclib in High-Risk HR+/HER2− Early Breast Cancer: A Real-World Study in Chinese Patients 中文标题：早期毒性驱动的剂量调整不影响高危HR+/HER2−早期乳腺癌辅助阿贝西利疗效：一项中国患者真实世界研究讲者：Jing Huang (Xi'an, China) 摘要号：1896eP 英文标题：Fruquintinib plus eribulin in patients with metastatic HR+, HER2- breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study 中文标题：呋喹替尼联合艾立布林治疗内分泌治疗联合CDK4/6抑制剂进展后的转移性HR+/HER2−乳腺癌：II期研究更新结果讲者：袁渊（南京医科大学第一附属医院）摘要号：1898eP 英文标题：Real-World Outcomes of First-Line CDK4/6 Inhibitors Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer: A Large National Cohort Study in China 中文标题：CDK4/6抑制剂联合内分泌治疗一线治疗HR+/HER2−晚期乳腺癌的真实世界结局：中国大型全国性队列研究讲者：罗扬（中国医学科学院肿瘤医院）摘要号：1903eP 英文标题：Patient-reported outcomes after switching from goserelin implant to goserelin microsphere in breast cancer: preliminary results of a prospective study 中文标题：乳腺癌患者从戈舍瑞林植入剂转换为戈舍瑞林微球后的患者报告结局：一项前瞻性研究初步结果讲者：张蓝心（大连医科大学附属第二医院）摘要号：1904eP 英文标题：CPS-EG Combined With Postoperative Ki-67 Outperforms ypTNM for Prognostication in HR+/HER2- Breast Cancer After Neoadjuvant Therapy: An 801-Patient Single-Center Retrospective Cohort Study 中文标题：CPS-EG联合术后Ki-67对HR+/HER2−乳腺癌新辅助治疗后预后的预测价值优于ypTNM：一项801例患者单中心回顾性队列研究讲者：Tian Yi Zhou (Guangzhou, China) 摘要号：1907eP 英文标题：Real-World Effectiveness and Safety of the Novel Agent Inavolisib in Heavily Pretreated, PIK3CA-mut Advanced Breast Cancer: A Multicenter Study of Patients with More Advanced and Complex Disease 中文标题：伊那利塞在重度经治PIK3CA突变晚期乳腺癌中的真实世界疗效与安全性：一项针对病情更晚期复杂疾病患者的多中心研究讲者：梁旭（北京大学肿瘤医院）摘要号：1911eP 英文标题：Optimal sequencing of systemic therapies for HR+/HER2− advanced breast cancer stratified by visceral and liver metastases: a systematic review and network meta-analysis 中文标题：按内脏和肝转移分层HR+/HER2−晚期乳腺癌全身治疗的最佳序贯策略：系统综述与网络荟萃分析讲者：Hong Cheng (Beijing, China) 摘要号：1918eP 英文标题：ABC-RWS-01 interim analysis of elacestrant in Chinese ESR1-mutated ER+/HER2- advanced breast cancer 中文标题：Elacestrant治疗中国ESR1突变ER+/HER2−晚期乳腺癌的ABC-RWS-01研究期中分析讲者：Wenbo Shi (Qionghai, China) 摘要号：1923eP 英文标题：Real-World Effectiveness and Safety of Maintenance Endocrine Therapy With or Without CDK4/6 Inhibitors Following Chemotherapy in HR-Positive/HER2-Negative Advanced Breast Cancer 中文标题：HR+/HER2-晚期乳腺癌化疗后维持内分泌治疗联合或不联合CDK4/6抑制剂的真实世界疗效与安全性讲者：李慧慧（山东省肿瘤医院）摘要号：1929eP 英文标题：Characterization of PIK3CA variants and real-world clinical evolution of first-line CDK4/6 inhibitors: Insights from a Chinese HR+/HER2- advanced breast cancer cohort 中文标题：PIK3CA变异特征与一线CDK4/6抑制剂治疗的真实世界临床演变：来自中国HR+/HER2−晚期乳腺癌队列的见解讲者：石晶（中国医科大学附属第一医院）摘要号：1936eP 英文标题：Safety profile of exemestane vs. anastrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports 中文标题：依西美坦对比阿那曲唑的真实世界安全性：FAERS数据库不相称性分析与病例报告系统综述讲者：Chunsu Liang (Beijing, China) 摘要号：1943eTiP 英文标题：SoGreat: A phase Ib modular study of sacituzumab govitecan plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer after progression on CDK4/6 inhibitors 中文标题：SoGreat：戈沙妥珠单抗联合内分泌治疗用于CDK4/6抑制剂进展后HR+/HER2-转移性乳腺癌的Ib期模块化研究讲者：Zhonghui Zheng (Shanghai, China) 摘要号：1944eTiP 英文标题：The NASA (Neoadjuvant Ribociclib plus Aromatase Inhibitor) Trial: A randomized comparison versus chemotherapy in HR+/HER2- EBC 中文标题：NASA试验（新辅助哌柏西利联合芳香化酶抑制剂）：HR+/HER2−早期乳腺癌中对比化疗的随机对照研究讲者：蔡子杰（中山大学孙逸仙纪念医院） Supportive care（支持治疗）摘要号：3950P 英文标题：Musculoskeletal pain, neutrophil recovery kinetics, and exploratory immune-profiling with telpegfilgrastim versus other long-acting G-CSFs in breast cancer: TELEGRAM 中文标题：乳腺癌中拓培非格司亭对比其他长效G-CSF的肌肉骨骼疼痛、中性粒细胞恢复动力学及探索性免疫分型：TELEGRAM研究讲者：李薇（南京医科大学第一附属医院）摘要号：4028eP 英文标题：Efficacy and safety of telpegfilgrastim in breast cancer patients undergoing (neo)adjuvant chemotherapy for prophylaxis of chemotherapy-induced neutropenia: A multicenter, prospective, observational study 中文标题：拓培非格司亭在乳腺癌（新）辅助化疗患者预防化疗所致中性粒细胞减少的疗效与安全性：一项多中心、前瞻性、观察性研究讲者：张少华（解放军总医院）摘要号：4057eP 英文标题：Prospective Cohort Study on the Prophylaxis of Catheter-related Thrombosis in Breast Cancer Patients 中文标题：乳腺癌患者导管相关血栓预防的前瞻性队列研究讲者：Shiyu Li (Beijing, China) 摘要号：4071eP 英文标题：Auricular point stimulation plus dexamethasone for nausea and vomiting caused by docetaxel combined with cyclophosphamide in breast cancer adjuvant chemotherapy (ADDC) 中文标题：耳穴刺激联合地塞米松用于乳腺癌辅助化疗多西他赛联合环磷酰胺所致恶心呕吐（ADDC研究）讲者：Juan Wang (Hangzhou, China) 摘要号：4138eP 英文标题：Physiological and Functional Responses to Ultrasound-Guided Dextrose Hydrodissection in Breast Cancer Survivors With Persistent Chest Wall and Axillary Tightness 中文标题：超声引导下葡萄糖水分离术对持续性胸壁和腋窝紧绷的乳腺癌幸存者的生理与功能反应讲者：Yuchun Lee（中国台湾台中市） Triple negative breast cancer（三阴性乳腺癌）摘要号：4651P 英文标题：Competing risk nomogram for cancer-specific mortality and risk-stratified treatment associations in women with T2N0M0 triple-negative breast cancer: a SEER study (2010-2016) 中文标题：T2N0M0三阴性乳腺癌患者癌症特异性死亡竞争风险列线图及风险分层治疗关联：一项SEER研究（2010-2016）讲者：Sirui Zhu (Beijing, China) 摘要号：4652P 英文标题：225Ac-PSMA-targeted alpha therapy (TRC003) in metastatic TNBC: A prospective, multicenter, single-arm safety/efficacy trial 中文标题：225Ac-PSMA靶向α核素治疗（TRC003）在转移性TNBC中的应用：一项前瞻性、多中心、单臂安全性与疗效试验讲者：孙晓蓉（山东第一医科大学附属肿瘤医院）摘要号：4653P 英文标题：A phase 2, multicenter, open-label study to evaluate the efficacy and safety of ATRA plus toripalimab and chemotherapy in patients with previously treated locally advanced or metastatic triple-negative breast cancer 中文标题：ATRA联合特瑞普利单抗和化疗治疗经治局部晚期或转移性三阴性乳腺癌的II期多中心开放标签研究讲者：陶中华（复旦大学附属肿瘤医院）摘要号：4655P 英文标题：Efficacy and Safety of First-Line Treatment for Advanced Triple-Negative Breast Cancer: A Network Meta-Analysis of Randomized Controlled Trials 中文标题：晚期三阴性乳腺癌一线治疗的疗效与安全性：随机对照试验网络荟萃分析讲者：Junxiao Wang (Fuzhou, China) 摘要号：4657P 英文标题：Subtyping-guided addition of bevacizumab to treatment of physician's choice for previously untreated, advanced, basal-like immune-suppressed triple-negative breast cancer (OASIS/BCTOP-T-M01): a randomised, multicentre, phase 3 trial 中文标题：分型指导的贝伐珠单抗联合医生选择方案治疗初治晚期基底样免疫抑制型三阴性乳腺癌（OASIS/BCTOP-T-M01）：一项随机、多中心III期试验讲者：马林晓曦（复旦大学附属肿瘤医院）摘要号：4678P 英文标题：The Efficacy and Safety of Utidelone Plus Tislelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) 中文标题：优替德隆联合替雷利珠单抗和贝伐珠单抗治疗晚期或转移性三阴性乳腺癌（UTILIZABLE研究）讲者：Qingxu Liu (Wuhan, China) 摘要号：4680eP 英文标题：Identification of angiogenesis-related diagnostic and prognostic gene signatures for triple-negative breast cancer via machine learning and single-cell analysis 中文标题：基于机器学习和单细胞分析鉴定三阴性乳腺癌血管生成相关诊断和预后基因特征讲者：Hanbo Wang (Tianjin, China) 摘要号：4682eP 英文标题：Isojacareubin induces apoptosis of chemoresistant-triple negative breast cancer by epigenetic repression of PIK3CA via deacetylation of Histone 3 lysine 56 中文标题：异山竹素通过组蛋白H3K56去乙酰化表观遗传抑制PIK3CA诱导化疗耐药三阴性乳腺癌凋亡讲者：Dar-Ren Chen（中国台湾彰化市）摘要号：4686eP 英文标题：Single-cell transcriptomics reveals drivers of tumor microenvironment reprogramming and immunotherapy resistance in triple-negative breast cancer 中文标题：单细胞转录组学揭示三阴性乳腺癌肿瘤微环境重编程和免疫治疗耐药的驱动因素讲者：Shuangqi Qian (Tianjin, China) 摘要号：4690eP 英文标题：Association of PCSK9 Inhibitor Use With Breast Cancer Survival and Recurrence: A Target Trial Emulation 中文标题：PCSK9抑制剂使用与乳腺癌生存和复发的关联：目标试验模拟讲者：Salida Ali（中国香港）摘要号：4693eP 英文标题：PD-1 Inhibitor Sintilimab Concurrent with Epirubicin, Cyclophosphamide, and Nab-Paclitaxel as Neoadjuvant Therapy for Triple-Negative Breast Cancer: A Single-Arm, Phase II Study 中文标题：PD-1抑制剂信迪利单抗联合表柔比星、环磷酰胺和白蛋白紫杉醇新辅助治疗三阴性乳腺癌：一项单臂II期研究讲者：Duanyang Zhai (Guangzhou, China) 摘要号：4695eP 英文标题：Carboplatin plus taxanes combined with or without PD-1 inhibitors as neoadjuvant therapy in triple-negative breast cancer: A Propensity-Matched Cohort Study 中文标题：卡铂联合紫杉类联合或不联合PD-1抑制剂新辅助治疗三阴性乳腺癌：一项倾向性匹配队列研究讲者：Hongwei Lyu (Beijing, China) 摘要号：4700eP 英文标题：Radiological Complete Response as a Predictor of Neoadjuvant Therapy Efficacy in Early Triple-Negative Breast Cancer: A Multicenter Real-World Study 中文标题：影像学完全缓解作为早期三阴性乳腺癌新辅助治疗疗效的预测因素：一项多中心真实世界研究讲者：Wenyu Yang (Beijing, China) 摘要号：4702eP 英文标题：A Tumor Cell Membrane-Based FTY720 Nanoplatform Synergizes with [177Lu]Lu Radionuclide Therapy for Triple-Negative Breast Cancer 中文标题：基于肿瘤细胞膜的FTY720纳米平台协同[177Lu]Lu放射性核素治疗三阴性乳腺癌讲者：Yuyue Hou (Wuhan, China) 摘要号：4724eP 英文标题：Predictive value of tertiary lymphoid structures for immunotherapy efficacy in triple-negative breast cancer 讲者：三级淋巴结构对三阴性乳腺癌免疫治疗疗效的预测价值讲者：刘月平（河北医科大学第四医院）摘要号：4732eP 英文标题：Landscape of Peripheral Immune Response Induced by Multimodal Thermal Therapy Combined with Chemoimmunotherapy in Patients with Early-stage Triple-negative Breast Cancer 中文标题：多模式热疗联合化学免疫治疗诱导早期三阴性乳腺癌患者外周免疫应答的全景分析讲者：Fei Lin Qu (Shanghai, China) AI for clinical workflows and decision-making（人工智能辅助临床工作流程与决策）摘要号：208P 英文标题：Multimodal Unified Survival Ensemble (MUSE) Predicts Immunotherapy Survival Benefit in Triple-negative Breast Cancer (TNBC): Analysis from the TORCHLIGHT Study 中文标题：多模态统一生存集成模型预测三阴性乳腺癌免疫治疗生存获益：TORCHLIGHT研究分析讲者：江泽飞（解放军总医院） AI for diagnostics and profiling (pathology, radiology, molecular biology)（人工智能辅助诊断与分子分型）摘要号：300P 英文标题：BRIGHT: a breast pathology foundation model for biomarker prediction and treatment stratification in breast cancer 中文标题：BRIGHT：用于乳腺癌生物标志物预测与治疗分层的基础病理模型讲者：刘芳芳（天津医科大学肿瘤医院）摘要号：314P 英文标题：Study on the association between HER2 expression in breast cancer and spatial heterogeneity of microvascular density 中文标题：乳腺癌HER2表达与微血管密度空间异质性的关联研究讲者：Jingyue Li (Shenyang, China) 摘要号：331P 英文标题：An Interpretable Whole-slide Image Framework for Automated Trop-2 H-score Assessment in Breast Cancer 中文标题：可解释的全玻片图像框架用于乳腺癌Trop-2 H-score自动评估讲者：刘月平（河北医科大学第四医院）摘要号：355P 英文标题：A Multimodal Model Integrating Therapeutic Response Patterns and AI-Powered Pathology for Survival Prediction in Breast Cancer After Neoadjuvant Therapy 中文标题：整合治疗反应模式与人工智能病理的多模态模型用于乳腺癌新辅助治疗后生存预测讲者：刘月平（河北医科大学第四医院） Developmental therapeutics（药物研发）摘要号：1119eP 英文标题：Nitazoxanide Induces Ferroptosis in Triple-Negative Breast Cancer by Dual Reprogramming of Iron Metabolism and the β-catenin/GPX4 Axis 中文标题：硝唑尼特通过双重重编程铁代谢和β-catenin/GPX4轴诱导三阴性乳腺癌铁死亡讲者：Tao He (Luzhou, China) Psycho-oncology（心理肿瘤学）摘要号：3495eP 英文标题：Machine Learning Models for Depression Risk Prediction in Breast Cancer Patients: A Cross-Sectional Study Based on the NHANES Database 中文标题：基于NHANES数据库的机器学习模型预测乳腺癌患者抑郁风险：一项横断面研究讲者：Junxiao Wang (Fuzhou, China) Translational research and biomarkers（转化研究与生物标志物）摘要号：4587eP 英文标题：Temperature-Responsive PDDNFs@QDs Integrating Simplified Isolation for Efficient Exosome Analysis Enables Breast Cancer Diagnosis and Subtyping 中文标题：温敏型PDDNFs@QDs整合简化分离实现高效外泌体分析用于乳腺癌诊断与分型讲者：Xiangyue Meng (Chengdu, China) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

抗体药物偶联物临床2期临床结果

2026-07-20

·ioncology

指南优解丨赵丽瑛教授：展望未来，新型ADC药物开启胃癌全新抗HER2治疗之路

点击蓝字，关注我们编者按：随着新型ADC药物德曲妥珠单抗（T-DXd）于2026年1月获中国国家药品监督管理局（NMPA）批准单药治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性 HER2 阳性胃癌或胃食管结合部腺癌患者，并于2026年4月被《中国临床肿瘤学会（CSCO）胃癌诊疗指南》确立为HER2阳性胃癌二线治疗的唯一I级推荐方案（1A 类证据），HER2阳性胃癌的抗HER治疗正式迈入新型抗体偶联药物（ADC）主导的精准治疗新阶段。从系列科学研究DESTINY-Gastric01在后线治疗中破冰，到DESTINY-Gastric04以III期证据确立二线标准，DESTINY-Gastric系列科学研究不仅改写了HER2阳性晚期胃癌的治疗格局，也为ADC药物在胃癌领域的后续研发与临床探索探索提供了重要的循证参考。本期“指南优解”特邀南方医科大学南方医院赵丽瑛教授，立足DESTINY-Gastric系列科学研究的成功经验，展望新型ADC药物在胃癌治疗中的临床应用前景。后线破冰： DG01与DG06奠定新型ADC治疗基石在T-DXd问世之前，HER2阳性胃癌的后线治疗长期处于疗效瓶颈期，既往后线治疗的中位总生存期（OS）仅为5-6个月，客观缓解率（ORR）不足15%[1-2]，患者预后较差。抗HER2新型ADC药物的研发很大程度上改变了这一治疗困境。 DESTINY-Gastric01（DG01）是一项开放标签、多中心、随机II期研究，纳入来自日本和韩国的187例HER2阳性（IHC 3+或IHC 2+/ISH+）晚期胃癌/胃食管结合部癌患者，这些患者均在接受包括曲妥珠单抗在内的两种或以上治疗后出现疾病进展。患者按2:1随机分配至T-DXd组或医生选择的化疗组。DG01研究的结果在2020年ASCO年会公布并同步发表于《新英格兰医学杂志》，成为胃癌治疗史上的重要里程碑：T-DXd组中位OS达到12.5个月，而化疗组仅为8.4个月，死亡风险显著降低41%（HR=0.59，P<0.0001）；T-DXd组和化疗组的中位无进展生存期（PFS）则分别为5.6个月和3.5个月，死亡或进展风险显著降低53%（HR=0.47，P=0.0003）。ORR方面，T-DXd组高达51%，化疗组仅为14%（P<0.001）。为进一步验证T-DXd在中国人群中的疗效与安全性，国内开展了单臂、多中心II期DESTINY-Gastric06（DG06）研究[4]，纳入95例既往接受过至少两种治疗（包括曲妥珠单抗）的HER2阳性晚期胃癌/胃食管结合部癌患者，其中73例经中心确认HER2阳性。结果显示，独立评审委员会确认的ORR为28.8%，中位PFS为5.7个月，中位OS为11.1个月。在安全性方面，中国人群的耐受性表现良好，≥3级间质性肺病（ILD）发生率为0%，未发现新的安全性信号，为T-DXd在中国人群中的应用提供了关键的本土循证依据。二线领航： DG02与DG04确立治疗新标准 DESTINY-Gastric02（DG02）[5]是一项在西方人群开展的单臂II期研究，评估T-DXd在HER2阳性晚期胃癌/胃食管结合部癌二线治疗中的疗效。研究纳入79例在含曲妥珠单抗一线治疗期间或之后出现疾病进展的患者，接受T-DXd 6.4 mg/kg每3周一次治疗。更新分析（中位随访10.2个月）显示ORR达42%，中位缓解持续时间为8.1个月，该研究在西方人群中证实了T-DXd二线治疗的疗效，为后续III期确证性研究的开展奠定了基础。随后开展的DESTINY-Gastric04（DG04）研究[6]是一项国际多中心、随机、对照III期临床研究，共纳入494例曲妥珠单抗联合化疗经治的HER2阳性（IHC 3+或IHC 2+/ISH+）局部晚期或转移性胃癌/胃食管结合部癌患者，按1:1随机分配至T-DXd单药组或RAM+PTX标准方案组。在主要终点OS方面，DG04研究结果显示T-DXd组中位OS达到14.7个月，而对照组仅为11.4个月，死亡风险显著降低30%（HR=0.70，P=0.0044）。在次要终点方面，T-DXd同样展现出优势：中位PFS为6.7个月 vs 5.6个月（HR=0.74，P=0.0074）；ORR高达44.3%，而对照组仅为29.1%（P=0.0006）。在中国大陆及其他地区亚组人群中，T-DXd的表现同样优秀：中位PFS为7.2个月 vs 5.6个月（HR=0.62）；中位OS为14.8个月 vs 9.7个月（HR=0.78），为国内临床应用提供了强有力的循证支持。 △DESTINY-Gastric04研究OS、PFS结果指南落地：新型ADC药物改写二线治疗格局基于DESTINY-Gastric系列科学研究的充分循证证据，2026年4月，新版《CSCO胃癌诊疗指南》[7]正式发布，针对HER2阳性晚期胃癌的二线治疗做出重大更新，将T-DXd列为针对HER2高表达人群的唯一Ⅰ级推荐方案（1A类证据）。此次指南推荐级别的更新，既是临床循证证据积累的必然结果，也标志着HER2阳性晚期胃癌的全程抗HER2治疗体系已趋于完善。从一线的曲妥珠单抗±帕博利珠单抗、到二线的T-DXd、再到三线的T-DXd及其他ADC药物，覆盖全病程的精准治疗布局已基本形成。 △2026版CSCO胃癌诊疗指南二线治疗推荐在国际指南层面，2026年v1版《NCCN胃癌临床实践指南》将T-DXd列为HER2阳性晚期胃癌二线及以上治疗的优选高级别推荐方案（Preferred Category 1）[8]，《ESMO泛亚洲临床实践指南（2024）》同样给予T-DXd高级别推荐[9]。国内外权威指南的一致认可，标志着T-DXd已成为全球范围内HER2阳性胃癌二线治疗的新标准。结语回望DESTINY-Gastric系列科学研究的探索历程，从后线破冰到二线领航，再到指南落地，新型ADC药物为胃癌抗HER2全程治疗搭建了更清晰的临床框架。展望未来，随着更多循证证据的积累与指南指导下临床实践的不断规范，胃癌的精准诊疗水平将稳步提升，助力实现“健康中国2030”提出的提高癌症患者整体生存率的目标。参考文献：（滑动查看） [1]Sakai D, Omori T, Fumita S, et al. Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study. Int J Clin Oncol. 2022;27(7):1154-1163. doi:10.1007/s10147-022-02162-4 [2]Takeshi Omori,et al.Effectiveness of third- or later-line therapy in patients with HER2-positive advanced gastric cancer: Results from an observational retrospective study in Japan.J Clin Oncol 40, 277(20 [3] Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419-2430. [4] Peng Z, Chen P, Lu J, et al. Trastuzumab deruxtecan in patients from China with previously treated HER2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial. EClinicalMedicine. 2025;87:103404. [5]Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744-756. [6] Shitara K, Van Cutsem E, Gümüş M, et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025;393(4):336-348. [7] 中国临床肿瘤学会（CSCO）指南工作委员会. CSCO胃癌诊疗指南(2026). 人民卫生出版社. [8] National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric Cancer. Version 1.2026. [9] Shitara K, Fleitas T, Kawakami H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. ESMO Open. 2024;9(2):102226. 赵丽瑛教授南方医科大学南方医院普通外科副主任医师副教授硕士生导师中国临床肿瘤学会(CSCO)青年专家委员会委员中国抗癌协会胃部肿瘤整合康复专业委员会委员广东省临床医学学会肿瘤学专业委员会副主任委员广东省肿瘤康复学会消化肿瘤内科专委会常委广东省医学会消化肿瘤学专委会消化道肿瘤MDT学组副组长广东省医学会胃肠外科学分会委员广东省抗癌协会遗传性肿瘤专委会委员广州抗癌协会胃癌专委会常委广州市医学会肿瘤学分会委员本资料仅供医疗卫生专业人士参考，请勿向非医疗卫生专业人士发放 CN-20260715-00006，有效期2026年12月31日（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

2026-07-20

·BiG生物创新社

谁在兑现BD，谁只拿到了首付款？

过去两年，MNC频频来中国扫货，大额BD交易不断，从几亿、几十亿到上百亿美元，首付款也不断创下新高。据统计，2026年上半年中国海外BD交易金额达997亿美元，约为2024年全年的2倍，接近2025年全年的73%。这些海外BD既是中国biotech管线能够继续推进的战略资源，也是创新药赛道股价触底回升的重要基本面支撑。经过过往BD交易的洗礼，现在大家收到新的海外BD公告，可能已经见怪不怪了，更多的也许不是在关心首付有多少、总包有多少，而是会思考一个更重要的问题，这个BD出去的管线，究竟能走多远？交易条款的里程碑付款，到底是一个大饼，还是能实实在在落袋的现金流？从历史交易来看，即使经过了大公司的精挑细选、严谨评估和持续赋能，license out的管线成功率相比行业均值也并未有大的提升。那些达成BD交易的项目，有的在持续推进，拿到监管里程碑，甚至获批和商业化；有的则仍在临床开发，但离真正兑现还很远；也有一些项目被暂停、退回，最终只留下首付款和一段曾轰动一时的公告。达成BD交易只是第一阶段的胜利，意味着中国创新药早期管线已被全球药企看见和认可。第二阶段，是我们的管线可以被MNC验证，在海外实现临床成功，并持续兑现监管里程碑付款。第三阶段，则是获得海外医生和患者认可，被全球市场买单。现在，行业正在进入第二阶段。 01 真正跑出来的BD，长什么样？先看一个已经把交易总包变成真实收入的案例。2019年，阿斯利康与第一三共围绕Enhertu达成合作，首付款13.5亿美元，另有最高55.5亿美元的或有付款。真正让这笔交易成为经典案例的，并不是签约时那个68亿美元的总包，而是此后不断扩大的适应症和持续触发的里程碑。到2025年三季度，阿斯利康披露约15亿美元或有付款已经支付；2025年Enhertu全球合计销售额接近50亿美元，第一三共收到5.37亿美元的销售里程碑付款。BD合同里的潜在价值，已经逐步变成真实收入。中国创新药里，和黄医药与武田的呋喹替尼是较标准的“兑现型”案例。2023年，武田以4亿美元首付款获得呋喹替尼中国内地、香港和澳门以外的全球权益。FRUZAQLA随后在美国、欧洲和日本获批，FDA批准触发3500万美元付款，2024年销售达到约定门槛后又触发首笔2000万美元商业里程碑。传奇生物与Janssen合作开发的CARVYKTI则更进一步。截至2025年，传奇生物已累计取得7.6亿美元首付款和里程碑，合作收入也开始主要由CARVYKTI销售增长驱动。此时最重要的已不是最初合同写了多少，而是产品能否前移治疗线次、扩大产能并转化为市场份额。 BMS与百利天恒/围绕BL-B01D1的合作，则正在跨过临床验证关口。2023年，BMS支付8亿美元首付款获得其大中华区以外权益。2025年9月，IZABRIGHT-Breast01达成里程碑，触发第一笔2.5亿美元付款，2026年7月，随着IZABRIGHT-Lung02的启动，第二笔2.5亿美元里程碑如约而至。百利天恒至今已收到13亿美元付款，BL-B01D1也已获得NMPA附条件批准上市。 02 大单之后，也会出现分化当然，不是所有BD都会顺利变成Enhertu、CARVYKTI或FRUZAQLA。有些项目没有明确失败，合作也没有正式终止，但临床推进慢、里程碑迟迟没有触发，合作方在财报和研发日里提到它的次数越来越少；另一些项目则更直接地走向暂停、退回或终止。这并不反常。MNC签下一项早期资产，往往不是因为它确定项目会成功，而是在可接受的首付款成本下买一张未来市场的门票。大部分总包金额都附有严格条件，只有完成临床、获批或达到销售门槛才会支付。默沙东与第一三共合作的HER3-DXd就是一个例子。2024年，该项目因第三方生产设施检查收到FDA完全回应函；2025年，双方又因确证性Ⅲ期研究OS未达到统计学显著，撤回其肺癌适应症BLA。这说明即使是顶级MNC和成熟ADC平台，也绕不开CMC和确证性临床这些硬门槛。更直接的是GSK与iTeos的belrestotug。GSK曾支付6.25亿美元首付款押注这款TIGIT抗体，最终却因中期分析没有达到继续开发标准而终止合作。首付款很高，仍然不能替代数据。中国资产也已进入同一套筛选机制。百济神州曾将替雷利珠单抗和TIGIT抗体ociperlimab的部分海外权益交给诺华，首付款分别为6.5亿美元和3亿美元。2023年，两项合作先后终止。后来，ociperlimab因Ⅲ期研究预判难以达到OS终点而停止开发，替雷利珠单抗则依靠公司全球体系获得海外批准，并在2025年实现7.37亿美元的销售。同一家公司、同一个合作方，两个项目最终走出了完全不同的路径。这也提示我们，权益退回不一定等于分子失败，合作仍在也不代表项目安全。判断BD后续质量，不能只看合作有没有终止，而要追踪临床试验是否按时启动和完成、合作方投入是否增加、关键终点是否达成，以及项目是否仍被放在核心产品规划中。首付款是MNC对当时证据的定价，不是对未来成功的担保。 03 管线之外，公司也在被重新筛选一笔BD签完之后，被验证的不只是项目本身。更隐蔽的一层验证，是中国药企能不能真正进入全球药物开发体系。这件事过去被低估了。在单纯license-out时代，中国公司把资产卖出去，海外合作方负责后续开发、注册和商业化。看起来，卖方只要拿钱就可以了。但随着合作结构越来越复杂，情况已经变了。现在很多合作不再是简单交割，而是共同开发、联合临床、区域权益划分、数据共享、生产协同，甚至共同参与全球注册策略。这意味着，中国公司要被考察的能力，已经不只是能不能做出一个好分子。它还包括：能不能稳定提供CMC支持，能不能配合全球多中心临床，能不能按照MNC节奏完成补充研究，能不能在数据解读上与海外团队达成一致，能不能在项目受挫时快速调整适应症和开发路径。很多项目签约时看起来差不多，但几年后差距会拉开。不是因为分子一开始就有天壤之别，而是因为合作进入深水区后，背后的组织能力开始暴露。这也是为什么一些中国药企开始从单个资产授权，走向更复杂的组合式合作。辉瑞与信达的合作不是只买一个产品，而是覆盖多个早期肿瘤项目；恒瑞与BMS的合作也不是简单license-out，而是把资产、区域权益和共同发现项目放进同一个框架；礼来与海思科的合作同样指向早期发现能力，而不是某个已经被市场充分看见的成熟资产。这些合作背后，MNC看中的不只是项目本身，而是中国公司能不能持续产出、持续协作、持续交付。这会把中国创新药带入一个新的竞争层面。过去比的是谁能更快做出一个有交易价值的资产；接下来比的是谁能把这个资产放进全球体系后，还能跟得上MNC的开发节奏。真正成熟的BD，不是把资产卖出去之后就结束，而是中国公司和MNC一起把项目往前推。中国创新药出海的下一步，不只是被买走，而是能不能被长期协作。写在最后中国创新药BD热潮不是假的。MNC确实比过去更重视中国资产，中国公司也已经是全球药物研发的核心创新来源。但BD热潮需要进入下一层叙事。如果说过去两年，中国创新药证明的是我们的资产能被买走；那么接下来几年，行业要证明的就是我们的项目能在全球体系里持续推进。能不能拿到下一笔里程碑，能不能完成全球关键性临床，能不能获批、卖出收入，并让合作方继续加码，这些才是BD下半场真正的答案。首付款之后，中国创新药开始交作业。而这份作业，最终不是交给资本市场和新闻稿看的。它要交给临床、监管、医生、患者和全球药品市场。 Ref https://hkexir.beonemedicines.com/zh-hant/news/2025r/6559b41c-7beb-45ca-bc76-5e1c9cdb26cc https://www.daiichisankyo.com/investors/ https://www.hutch-med.com/2025-full-year-results/ https://ir.baili-pharm.com/cn/investor-relations/ https://mp.weixin.qq.com/s/HlyJp9vr1EVk3-4aKiXTrw 近期活动第12届 BiG IMPACT年会10月23-24日将在上海张江正式启幕，本次年会汇聚哈佛院士、RA Capital等全球顶级产学研投力量，打造中国创新对话世界的稀缺跨境平台；早鸟6折优惠截至8月31日，点击报名锁定国际前沿盛宴！时间及地点：10月23-24日（周五-周六）上海-张江希尔顿；规模：800-1000人报名入口 ▼ 参会通道 VIP 门票：3000 元 / 人；含：全部论坛 + 闭门会 + 23 日晚宴 + 24 日午餐会议门票：1000元/人；含：10月23-24日公开会议 * 以上付费门票 8月31日前可享早鸟价 6折优惠会员 / 特邀通道：免费；审核制（限 BiG 会员 / 特邀 / 往届 speaker），权益同VIP门票院校 / 临床通道：免费；审核制（仅含10月23-24公开会议，不含午餐及晚宴）共建Biomedical创新生态圈！如何加入BiG会员？

引进/卖出细胞疗法免疫疗法

100 项与德曲妥珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	德曲妥珠单抗	L01XC	DB14962

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
HER2阳性转移性乳腺癌	美国	Daiichi Sankyo, Inc.	2026-05-15
胃癌	印度	AstraZeneca PLC	2025-10-07
HER2阳性实体瘤	英国	Daiichi Sankyo UK Ltd.	2025-04-09
HR阳性/HER2低表达乳腺癌	美国	Daiichi Sankyo Co., Ltd.	2025-01-28
HR阳性/HER2阳性乳腺癌	韩国	Daiichi Sankyo Co., Ltd.	2022-09-19
HER2突变型非小细胞肺癌	美国	Daiichi Sankyo, Inc.	2022-08-11
HER2阳性胃腺癌	澳大利亚	AstraZeneca Pty Ltd.	2021-10-08
HER2低表达乳腺癌	澳大利亚	AstraZeneca Pty Ltd.	2021-10-08
转移性乳腺癌	加拿大	AstraZeneca Canada, Inc.	2021-04-15
HER2阳性胃食管结合部腺癌	美国	Daiichi Sankyo, Inc.	2021-01-15
HER2阳性胃癌	日本	Daiichi Sankyo Co., Ltd.	2020-09-25
HER2阳性乳腺癌	美国	Daiichi Sankyo, Inc.	2019-12-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
实体瘤	临床3期	美国	Daiichi Sankyo, Inc.	2025-12-23
实体瘤	临床3期	中国	Daiichi Sankyo, Inc.	2025-12-23
实体瘤	临床3期	日本	Daiichi Sankyo, Inc.	2025-12-23
实体瘤	临床3期	澳大利亚	Daiichi Sankyo, Inc.	2025-12-23
实体瘤	临床3期	巴西	Daiichi Sankyo, Inc.	2025-12-23
实体瘤	临床3期	法国	Daiichi Sankyo, Inc.	2025-12-23
实体瘤	临床3期	以色列	Daiichi Sankyo, Inc.	2025-12-23
实体瘤	临床3期	意大利	Daiichi Sankyo, Inc.	2025-12-23
实体瘤	临床3期	韩国	Daiichi Sankyo, Inc.	2025-12-23
实体瘤	临床3期	西班牙	Daiichi Sankyo, Inc.	2025-12-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2026	N/A	实体瘤	15,810	Ado-trastuzumab emtansine	蓋範衊簾築蓋鹽襯觸選(願窪窪繭製襯糧顧憲簾) = 襯廠艱糧觸窪獵糧鹽艱繭繭構鏇鹹鹹鬱醖積積 (鑰網夢範鏇齋壓壓憲鬱 ) 更多	积极	2026-05-29
				Enfortumab vedotin	獵艱鑰鏇廠醖衊壓糧夢(鬱壓鬱築齋窪鬱襯積獵) = 顧願遞艱積觸繭鹹簾範鏇壓壓糧餘艱顧遞淵憲 (餘鑰鑰糧繭鏇齋齋醖廠 ) 更多
ASCO2026	N/A	晚期乳腺癌 HER2-positive \| HER2-low	119	Trastuzumab deruxtecan (BMI < 24 kg/m2)	齋鑰簾範觸築願窪繭繭(構艱夢廠範蓋夢鹹構齋) = 蓋鏇艱蓋壓網衊窪製夢醖製觸憲鹽廠醖鹹築積 (築醖鑰衊淵襯艱鬱蓋範 ) 更多	积极	2026-05-29
				Trastuzumab deruxtecan (BMI ≥24 kg/m2)	齋鑰簾範觸築願窪繭繭(構艱夢廠範蓋夢鹹構齋) = 遞膚構衊鑰顧醖廠廠窪醖製觸憲鹽廠醖鹹築積 (築醖鑰衊淵襯艱鬱蓋範 ) 更多
NCT06819007 (DESTINY-Ovarian01, ASCO2026)	临床3期	一线 \| 维持 HER2-expressing	21	T-DXd + BEV	廠觸鏇選構衊鏇觸淵衊(積選醖壓衊夢鑰鹽顧夢) = 憲夢構艱鹹糧積鹹遞構遞艱淵製網鹽獵鑰醖願 (遞顧鹽壓網艱醖鹹蓋網 ) 更多	积极	2026-05-29
ASCO2026	N/A	转移性乳腺癌 HER2-positive \| HER2-low	406	Trastuzumab deruxtecan	淵艱夢淵蓋範製鏇鑰餘(餘襯遞選獵遞製觸鹽簾) = 夢艱願築簾餘鏇艱願壓襯積夢積壓繭壓壓鏇範 (壓夢構餘範網艱憲鹽憲 ) 更多	积极	2026-05-29
ASCO2026	N/A	HER2阳性乳腺癌 HER2-positive \| HER2-low	63	Dose-adapted trastuzumab deruxtecan	艱範願簾衊餘鹹築獵齋(製壓廠窪窪壓淵製顧醖) = 遞廠鹽醖膚衊艱廠醖網壓構窪獵築鏇艱繭淵齋 (夢蓋衊願鹽獵鹽鑰襯醖, 46 ~ 71) 更多	积极	2026-05-29
				Dose-adapted trastuzumab deruxtecan (Evaluable cohort)	艱範願簾衊餘鹹築獵齋(製壓廠窪窪壓淵製顧醖) = 選選憲繭廠膚繭襯繭獵壓構窪獵築鏇艱繭淵齋 (夢蓋衊願鹽獵鹽鑰襯醖, 53 ~ 79) 更多
ASCO2026	N/A	肿瘤 \| 乳腺癌	30	Low-dose 2.7mg/kg	膚願膚憲蓋構淵餘壓鏇(襯築蓋糧遞憲鹹構積構) = only one patient had grade 1 lung toxicity. She received SBRT to two lesions prior to TDxD. One patient experienced grade 4 diarrhea. 齋範遞壓構鏇構鬱夢蓋 (壓衊餘壓顧糧觸糧鬱鹽 ) 更多	积极	2026-05-29
				Standard-dose 5.4mg/kg
ASCO2026	N/A	HER2阳性实体瘤 HER2-positive	235	Trastuzumab deruxtecan	窪糧獵鬱鬱膚範願壓製(鹹襯構膚廠範蓋衊膚襯) = 艱窪觸顧鑰獵壓築範醖艱衊遞鏇憲鏇襯齋醖積 (衊醖膚襯壓構餘夢襯築 ) 更多	积极	2026-05-29
ASCO2026	N/A	晚期乳腺癌	82	trastuzumab deruxtecan	鬱齋壓膚網觸鏇網觸觸(壓淵願遞糧製簾蓋鬱膚) = 齋糧鑰醖膚遞構壓積範艱範淵鑰憲廠淵膚鏇簾 (糧範夢網夢夢壓窪醖積 ) 更多	积极	2026-05-29
				trastuzumab emtansine	鬱齋壓膚網觸鏇網觸觸(壓淵願遞糧製簾蓋鬱膚) = 壓壓蓋艱蓋艱窪鑰範範艱範淵鑰憲廠淵膚鏇簾 (糧範夢網夢夢壓窪醖積 )
NCT04494425 (DESTINY-Breast06, ASCO2026)	临床3期	HER2阳性转移性乳腺癌	49	trastuzumab deruxtecan (Adherent to ILD/pneumonitis TMGs)	廠淵選齋鹽壓積範齋鹽(繭廠築網艱襯構繭築鹽) = 餘遞積襯繭憲構夢窪鏇觸製願顧蓋構鏇窪構觸 (範鏇鏇鹽壓襯網廠繭襯 ) 更多	积极	2026-05-29
				trastuzumab deruxtecan (Partially adherent to ILD/pneumonitis TMGs)	廠淵選齋鹽壓積範齋鹽(繭廠築網艱襯構繭築鹽) = 繭憲繭膚壓壓範齋繭窪觸製願顧蓋構鏇窪構觸 (範鏇鏇鹽壓襯網廠繭襯 ) 更多
NCT04704934 (DESTINY-Gastric04, ASCO2026)	临床3期	HER2阳性胃癌 \| 胃食管交界处腺癌二线 HER2+	494	trastuzumab deruxtecan (T-DXd) 6.4 mg/kg	製艱糧鑰構憲壓簾製鏇(鏇願醖鏇繭選簾憲淵網) = 範糧蓋窪蓋願簾鏇範遞膚鹽鹹網壓顧鹽鏇積衊 (鑰願製艱觸鹹顧鹹獵窪, 2.7 ~ 5.0) 更多	积极	2026-05-29
				ramucirumab + paclitaxel	製艱糧鑰構憲壓簾製鏇(鏇願醖鏇繭選簾憲淵網) = 淵窪築遞憲餘齋觸夢衊膚鹽鹹網壓顧鹽鏇積衊 (鑰願製艱觸鹹顧鹹獵窪, 2.1 ~ 3.5) 更多